An assessment of physician knowledge and understanding of the risks of vandetanib (Caprelsa®) within the European Union

Documents

Study protocol

Initial protocol

Final Caprelsa prescriber survey protocol (2) (2)

Study results

Study results

Vandetanib Physican Survey Study Report - 22JUN2018

Study report

Other information